New Zealand markets closed

BIIB Jan 2023 155.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.96000.0000 (0.00%)
As of 11:07AM EDT. Market open.
Full screen
Previous close4.9600
Open4.9600
Bid0.0000
Ask0.0000
Strike155.00
Expiry date2023-01-20
Day's range4.9600 - 4.9600
Contract rangeN/A
Volume1
Open interestN/A
  • Yahoo Finance Video

    Health care bill ‘most aggressive action’ on drug pricing: Analyst

    Raymond James Healthcare Policy Analyst Chris Meekins joins Yahoo Finance Live to discuss the expectations for the Manchin-Schumer deal, expanding regulation on drug prices, out-of-pocket Medicare expenses, and the outlook for pharmaceutical company earnings.

  • Motley Fool

    Good News for Retirees: Lower Medicare Part B Premiums Could Be Coming

    Millions of Americans are eagerly waiting to find out how much their Social Security cost-of-living adjustment (COLA) will be for 2023. One big reason why that's the case is that Social Security's COLA calculation doesn't include Medicare Part B premiums. You might wonder how Medicare Part B premiums could possibly decline.

  • GlobeNewswire

    The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

    Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary endpointBiogen is also evaluating litifilimab in systemic lupus erythematosus through the Phase 3 TOPAZ studies and plans to initiate a pivotal study in CLE later this yearBiogen is advancing two lupus therapies in Phase 3 trials to address this chronic autoimmune disease CAMBRIDGE, Mass., July 28, 2022 (